Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer

Funder NIHR (part of DHSC)
Recipient organisation NIHR Royal Marsden Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period Mar 2025 — Apr 2028

In plain English

AI plain-English summary

A new drug, ORIC-944, is being tested for the first time in humans to treat metastatic prostate cancer that has spread beyond the prostate. This matters because prostate cancer is the most common cancer in men, and when it spreads, current treatments eventually stop working. ORIC-944 targets a different biological pathway than existing drugs, potentially offering a new option for patients whose cancer has become resistant to standard therapies. The study is testing ORIC-944 alone and in combination with two approved drugs, apalutamide and darolutamide, which block androgen receptors. If this research succeeds, ORIC-944 could become part of a new treatment combination that delays disease progression longer than current therapies alone. The UK is participating only in Part III of the study, which tests two dose levels of ORIC-944 combined with darolutamide in 28-day cycles. Researchers will measure how much ORIC-944 reaches the bloodstream and assess safety and tolerability. A separate sub-study will also determine whether food affects how the body absorbs the drug. This is early-stage, dose-finding research—it will not immediately change clinical practice, but it is a necessary step toward identifying whether ORIC-944 warrants larger, later-stage trials.

View original technical description
Prostate Cancer is the most common cancer in men. If the cancer spreads to other areas, this is known as metastases. The treatment being investigated in this study is ORIC-944. This is the first time ORIC-944 is being administered to humans. Several doses of ORIC-944 will be tested. The research study consists of 3 parts:Part I: dose finding portion for ORIC-944 when administered as a single drug. This part of the study is complete.Part II: dose finding portion for ORIC-944 when administered in combination with apalutamide (Erleada™) or darolutamide (Nubeqa®), 2 different approved Androgen Receptor Pathway Inhibitor (ARPI), drugs that are used to treat prostate cancer. Part III: will further test 2 potential dose levels of ORIC-944 selected from Part II in combination with darolutamide to select the most tolerable and safe active dose.Additionally, a food effect sub-study is also being conducted to explore the effect of food on the amount of ORIC-944 absorbed by the body and its safety.The UK is participating in Part III of the study only. Darolutamide will be the ARPI provided in the UK.The primary purposes of Part III are to further evaluate the safety, tolerability, and activity of the 2 potential doses of ORIC-944 in combination with darolutamide, that were selected from Part II and to measure the amount to ORIC-944 in the participant’s blood when co-administered with darolutamide.Study treatment is based on daily dosing in 28-day treatment cycles until disease progression, if the treatment becomes intolerable or the participant withdraws consent.

Researchers

Johann De Bono (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

An Open-label, Randomised, Phase-I, Multi-Centre Study toInvestigate the Biological Effects of AZD5305 Alone, DarolutamideAlone, and in Combination Given Prior to Radical Prostatectomyin Men with Newly Diagnosed Prostate Cancer
Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer
GO44537 - A phase I open-label, multi-center, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of RO7656594 in patients with advanced or metastatic prostate cancer
PROpel: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
A randomized, double-blind, placebo-controlled Phase 3 study of IMP plus androgen deprivation therapy (ADT) compared to placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.